Karyopharm Therapeutics (KPTI)

Executive Summary

Karyopharm Therapeutics is a commercial-stage oncology company focused on discovering and developing novel drugs targeting nuclear export. Its lead product, XPOVIO (selinexor), is approved in multiple myeloma and diffuse large B-cell lymphoma (DLBCL). The company faces declining XPOVIO sales due to competition and limited label expansion. However, its pipeline includes several Phase 2 trials exploring selinexor in combination regimens for hematologic malignancies and solid tumors. Key ongoing studies include a Phase 2 trial in DLBCL (NCT02227251) with a primary completion in 2027 and a Phase 2 multiple myeloma combination trial (NCT04717700) targeting 2029. Karyopharm also has a partnership with Antengene for development in Greater China. Despite setbacks such as multiple terminated trials, the company's innovative mechanism (XPO1 inhibition) and potential for label expansions provide upside if data readouts are positive. Financially, Karyopharm has a modest market cap (~$190M estimated) and may require additional funding to support operations and trials. Investors should watch for interim data from ongoing studies and any strategic moves to preserve cash.

Upcoming Catalysts (preview)

• Q3 2026Interim data from Phase 2 DLBCL trial (NCT02227251)25% success
• TBDFDA decision on selinexor in additional indication (e.g., endometrial cancer or other solid tumors)15% success
• TBDPartnership or licensing deal for selinexor outside existing agreements20% success